Mitchell Bloom is national Chair of Goodwin’s Life Sciences practice. Mr. Bloom specializes in representing public and private life science companies, as well as venture capital firms and investment banks focused on the life sciences sector, including matters involving biotechnology, medical devices, diagnostics and healthcare information technology.

Chambers USA: America’s Leading Lawyers for Business, The Legal 500 and LMG Life Sciences have all recognized Mr. Bloom as a national industry leader for his corporate finance and life sciences expertise.

Experience

ERFAHRUNG

EXPÉRIENCE

工作经历

Mr. Bloom's practice is focused on the representation of emerging and public life science companies and he serves as principal outside or general counsel to leading life science companies. In addition to day-to-day corporate counseling and strategic advice to his clients, he regularly handles a variety of major business transactions, including public offerings, mergers and acquisitions, venture capital financings and strategic collaborations and commercial transactions.

His recent client representations include work with:

  • Ablynx NV in its $200 million initial public offering and €3.9 billion sale to Sanofi
  • Alnylam Pharmaceuticals in its $450 million and $805 million public follow-on public offerings and in its strategic alliance and $700 million equity financing with Genzyme
  • Aptinyx in its $118 million initial public offering, $65 million Series A financing and $70 million Series B financing
  • Assembly Biosciences in its $69 million public follow-on offering
  • BeiGene in its $158 million initial public offering and $200 million and $800 million follow-on public offerings
  • Celyad SA in its $100 million initial public offering
  • CRISPR Therapeutics AG in its joint venture with Bayer valued up to $335 million, $38 million additional Series B financing, $56 million initial public offering and $130 million follow-on offering
  • Cullinan Oncology in its $150 million Series A financing
  • DBV Technologies SA in its $92 million initial public offering
  • Eidos Therapeutics in its $122 million initial public offering
  • Esperion in its $70 million initial public offering and subsequent $97 million and $201 million follow-on public offerings
  • Galapagos NV in its $275 million initial public offering, $337 million follow-on public offering and strategic collaboration with Gilead Sciences valued up to $2 billion
  • Global Blood Therapeutics in its $120 million initial public offering and subsequent $120 million, $125 million and $100 million follow-on public offerings
  • HotSpot Therapeutics in its Series A financing
  • Inotek Pharmaceuticals in its $60 million initial public offering, $68.9 million and $50 million follow-on public offerings, and merger with Rocket Pharmaceuticals
  • Jounce Therapeutics in its $104 million initial public offering, $56 million Series B and $47 million Series A financings
  • Magenta Therapeutics in its $100 million initial public offering, $50 million Series B and Series A financings
  • Mevion Medical Systems in connection with its $55 million equity and debt financing
  • MyoKardia in its $46 million Series B financing and $54 million initial public offering and $143 million follow-on offering
  • Neon Therapeutics in its $100 million initial public offering, $70 million Series B financing and $55 million of Series A financing
  • Neos Therapeutics in its $75 million initial public offering
  • Nimbus Therapeutics in its sale of Nimbus Apollo to Gilead Sciences valued up to $1.2 billion, collaborations with Monsanto and Shire Plc and its $43 million Series B financing
  • Ocata Therapeutics in its $379 million sale to Astellas Pharma
  • Orchard Therapeutics in its $225 million initial public offering
  • ProQR Therapeutics B.V. in its $97.5 million initial public offering and $29 million public follow-on offering
  • Proteostasis Therapeutics in its $50 million initial public offering, $65 million and $40 million follow-on public offerings
  • Quartet Medicine in its $595 million strategic collaboration with Merck
  • RainDance Technologies in its sale to Bio-Rad Laboratories
  • Relay Therapeutics in its $57 million Series A financing and $63 million Series B financing
  • resTORbio in its $85 million initial public offering
  • Rheos Medicines in its $60 million Series A financing
  • SAGE Therapeutics in its $90 million initial public offering and subsequent $138 million, $150 million, $175 million, $345 million and $575 million follow-on public offerings
  • Tango Therapeutics in its $55 million Series A financing
  • TCR2 Therapeutics in its $44.5 million Series A financing and $125 million Series B financing
  • Voyager Therapeutics in its strategic collaboration with Genzyme for $100 million upfront and up to $745 million in milestone payments, and in its $45 million Series A financing, $60 million Series B financing and $70 million initial public offering
  • Warp Drive Bio in its innovative strategic partnership with Sanofi
  • Xeris Pharmaceuticals in its $98 million initial public offering
  • Zafgen in its $96 million initial public offering and subsequent $137 million follow-on public offering
  • Representation of underwriters in connection with public offerings for AC Immune, Edge Therapeutics, Flexion Therapeutics, InflaRX, Intrexon Corporation, NPS Pharmaceuticals, Ovid Therapeutics, Reata Pharmaceuticals, Roka Biosciences, Tokai Pharmaceuticals and Regulus Therapeutics
  • Representation of leading venture firms including Third Rock Ventures, Atlas Venture, Versant Ventures and 5AM Ventures
Professional Activities

Mr. Bloom is a member of the American, Massachusetts and Boston Bar Associations.

Professional Experience

Prior to joining Goodwin, Mr. Bloom was a partner at Testa, Hurwitz & Thibeault in Boston, where he was a member of the Business Practice Group and co-chair of its Life Sciences Practice.

Recognition

Mr. Bloom is recognized nationally for his leadership in the life sciences industry and has been included in numerous legal guides for his corporate finance and life sciences expertise, including Chambers USA: America’s Leading Lawyers for Business, U.S. News-Best Lawyers and The Legal 500 United States. In addition, for the past two years he has been selected as a “Life Science Star” by LMG Life Sciences.  Most recently, Mr. Bloom was recognized as the #1 most active U.S. attorney for issuer side IPOs in 2015.

Under his leadership, Goodwin’s Life Sciences practice has received numerous awards and honors, including U.S. News’ Biotechnology Law Firm of the Year for five of the last six years (2013-2015, 2017-2018) and perennial nationwide recognition by Chambers USA.

In The News

MELDUNGEN

ACTUALITÉS

相关新闻

Credentials

WERDEGANG

RÉFÉRENCES

专业资格

Education

J.D., 1989
Boston College Law School
B.S., 1986
Suffolk University

cum laude

Admissions

Bar

Massachusetts
Get In Touch
German Translation
NOUS CONTACTER
联系我们
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Unsere Kunden verlassen sich auf uns für erstklassige Beratungsdienste, beraten über komplexe Transaktionsarbeiten und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Industrie, verwenden wir eine kooperative, interdisziplinäre Ansatz zur Lösung unserer Kunden am schwierigsten Fragen. Um mehr zu erfahren, kontaktieren Sie uns bitte.

Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

客户信赖我们世界一流的咨询服务,希望获得针对复杂事务性工作与高风险诉讼的建议。我们通过协作式、跨领域的工作方法来解决客户最棘手的问题,涵盖金融、生命科学、私募股权、不动产和技术等多个行业。如需更多信息,请与我们联系。

Search Other Lawyers
ANWALTSSUCHE
Recherche par Pratique
搜寻其他律师